Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ELDERLY-PATIENTS. Found 6 abstracts

Prebet T, Sun ZX, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS. Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology. 2014 Apr;32(12):1242-8.   PMCID: PMC3986386
Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: A retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clinical lung cancer. 2007 Mar;8(5):319-26.
Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, Saville MW, Flinn I, Molina A. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 2007 Oct;22(5):684-91.
Langer C, Li SG, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599. Journal of Clinical Oncology. 2007 Feb;25(4):418-23.
Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV - ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3):277S-289S.
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ELDERLY-PATIENTS

ELDERLY-PATIENTS PHASE-III TRIAL CHEMOTHERAPY RANDOMIZED-TRIAL SUPPORTIVE CARE fourth-line therapy second-line therapy severe comorbidities or who refused treatment with radiation lesions presentations of CBCL rituximab VALPROIC ACID NEOPLASMS if m(2) Maintenance therapy lymphoma THERAPY CHEMOTHERAPY REGIMENS 5-AZACYTIDINE DOCETAXEL SYSTEMIC THERAPY cutaneous site of large-cell lymphoma that developed after 3 years in m(2) once every 2-3 months Objective SUPPORTIVE PATTERN FOLLICULAR-GROWTH DENDRITIC CELLS either primary CBCL or low-grade effective in treating of CBCL B-CELL LYMPHOMA PLATINUM contraindicated or unwanted Additional collaborative studies are remission One patient received local radiotherapy to a solitary lymphomas with relapses limited to the skin Rituximab appears to COMBINATION PROGNOSTIC-FACTORS each with either extensive established We treated five patients with rituximab given as a single agent for four weekly therapy B cell 19 ongoing complete clinical remissions with a median follow-up of 17 chemotherapy remission from the low-grade CBCL present an attractive alternative when radiation therapy is CYTOTOXIC T-CELLS VINORELBINE PLUS CISPLATIN ANTI-CD20 MONOCLONAL-ANTIBODY therapy EORTC CLASSIFICATION Oncology LOW-GRADE was given at 375 mg initiated VINDESINE PLUS CISPLATIN RADIOIMMUNOTHERAPY SINGLE-AGENT GEMCITABINE REGIMENS FOLLOW-UP CARE PHASE-II clinical responses occurred in all five patients Three patients have SINGLE-AGENT VINORELBINE IODINE I-131 TOSITUMOMAB no recurrences of either grade CBCL SURVIVAL ORAL VINORELBINE have yet occurred Treatment was well tolerated Rituximab is safe and METALLOPROTEINASE INHIBITOR BMS-275291 VINORELBINE LEUKEMIA GROUP-B TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be CANCER QUALITY-OF-LIFE FOLLICULAR LYMPHOMA COOPERATIVE-ONCOLOGY-GROUP non-small cell lung cancer chemotherapy-quality of life-targeted therapy at age 87 years from a non-related cause after 55 years of complete third-line GROUP-B cutaneous CHOP CHEMOTHERAPY VINDESINE HISTONE DEACETYLASE INHIBITION intravenous infusions of 375 mg PHASE-III ibritumomab tiuxetan radioimmunotherapy-non-Hodgkin's lymphoma-elderly CONVENTIONAL CARE REGIMENS NON-HODGKINS-LYMPHOMA needed to assess the role of rituximab in various clinicopathologic and 39 months post achievement of complete remission One patient died
Last updated on Wednesday, March 04, 2020